Personal CFO Solutions LLC Raises Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Personal CFO Solutions LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 10.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,177 shares of the medical research company’s stock after buying an additional 110 shares during the period. Personal CFO Solutions LLC’s holdings in IQVIA were worth $265,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in IQV. HighTower Advisors LLC increased its holdings in IQVIA by 2.4% in the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock valued at $1,168,000 after buying an additional 118 shares in the last quarter. Prudential PLC purchased a new position in IQVIA in the first quarter valued at about $741,000. Baird Financial Group Inc. increased its holdings in IQVIA by 2.3% in the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock valued at $23,021,000 after buying an additional 2,201 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in IQVIA by 59.0% in the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after buying an additional 144 shares in the last quarter. Finally, Covestor Ltd grew its position in shares of IQVIA by 82.2% in the first quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 250 shares during the last quarter. 86.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Constantinos Panagos sold 27,317 shares of IQVIA stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $208.67, for a total transaction of $5,700,238.39. Following the sale, the insider now owns 14,250 shares of the company’s stock, valued at approximately $2,973,547.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IQV. Citigroup increased their price target on shares of IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Guggenheim decreased their target price on shares of IQVIA from $253.00 to $220.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Stifel Nicolaus raised their target price on shares of IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Evercore ISI decreased their target price on shares of IQVIA from $260.00 to $240.00 in a research report on Wednesday, October 11th. Finally, Mizuho decreased their target price on shares of IQVIA from $250.00 to $229.00 and set a “buy” rating on the stock in a research report on Tuesday, October 10th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $236.57.

IQVIA Stock Performance

Shares of IQV stock opened at $205.29 on Tuesday. The company’s fifty day simple moving average is $197.22 and its 200-day simple moving average is $207.54. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $241.86. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 2.12. The company has a market cap of $37.47 billion, a PE ratio of 34.50, a P/E/G ratio of 2.64 and a beta of 1.42.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.